Becker's Healthcare April 9, 2024
Mariah Taylor

Biosimilars can now be substituted as part of regular formulary maintenance changes, according to CMS’ Medicare Advantage and Part D Final Rule for 2025. However, the change could significantly increase patient cost sharing, according to an article on the American Society of Health-System Pharmacists website.

The biosimilar substitution rule would apply to all enrollees, including those taking the reference product prior to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare Advantage, Patient / Consumer, Pharma / Biotech
Executive Outlook 2025: While MA ‘Tightens the Screws’ on Nursing Homes, Sector Focuses on Reform, Workforce Solutions, I-SNPs
Use Of Patient Health Survey Data For Risk Adjustment To Limit Distortionary Coding Incentives In Medicare
7 Medicare Advantage study findings to know
Florida Blue latest to sue over Medicare Advantage star ratings
MA Special Needs Beneficiaries More Likely to Receive Lower Quality Hospice Care

Share This Article